Literature DB >> 21692048

Survival after complete surgical resection of multiple metastases from renal cell carcinoma.

Angela L Alt1, Stephen A Boorjian, Christine M Lohse, Brian A Costello, Bradley C Leibovich, Michael L Blute.   

Abstract

BACKGROUND: Although a role for resection of solitary metastases from renal cell carcinoma (RCC) has been described, the utility of surgery in patients with multiple sites of disease has been less well defined. The authors report the survival of patients who underwent complete metastasectomy for multiple RCC metastases.
METHODS: The authors identified 887 patients who underwent nephrectomy for RCC between 1976 and 2006 who developed multiple metastatic lesions. The impact of complete metastasectomy on survival was evaluated controlling for the timing, location, and number of metastases and for patient performance status.
RESULTS: Of 887 patients, 125 (14%) underwent complete surgical resection of all metastases. Complete metastasectomy was associated with a significant prolongation of median cancer-specific survival (CSS) (4.8 years vs 1.3 years; P < .001). Patients who had lung-only metastases had a 5-year CSS rate of 73.6% with complete resection versus 19% without complete resection (P < .001). A survival advantage from complete metastasectomy also was observed among patients with multiple, nonlung-only metastases, who had a 5-year CSS rate of 32.5% with complete resection versus 12.4% without complete resection (P < .001). Complete resection remained predictive of improved CSS for patients who had ≥ 3 metastatic lesions (P < .001) and for patients who had synchronous (P < .001) and asynchronous (P = .002) multiple metastases. Moreover, on multivariate analysis, the absence of complete metastasectomy was associated significantly with an increased risk of death from RCC (hazard ratio, 2.91; 95% confidence interval, 2.17-3.90; P < .001).
CONCLUSIONS: The current results indicated that complete resection of multiple RCC metastases may be associated with long-term survival and should be considered when technically feasible in appropriate surgical candidates.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 21692048     DOI: 10.1002/cncr.25836

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  105 in total

Review 1.  Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma.

Authors:  Paul L Crispen; Michael L Blute
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

Review 2.  [Systemic and surgical management of metastatic renal cell carcinoma].

Authors:  M W Kramer; A S Merseburger; I Peters; S Waalkes; M A Kuczyk
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

Review 3.  [Metastasectomy for renal cell cancer].

Authors:  B Brehmer; C Piper; D Pfister; D Porres; A Heidenreich
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

4.  Cryosurgery/cryoablation in musculoskeletal neoplasms: history and state of the art.

Authors:  Peter S Rose; Jonathan M Morris
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

5.  Outcomes of Multi-disciplinary Management of Metastatic Renal Cell Carcinoma.

Authors:  Michael Yan; Richard Gregg; Aamer Mahmud
Journal:  Cureus       Date:  2019-10-13

6.  22-year survival following radical nephrectomy and several metastasectomies in a case of renal cell carcinoma.

Authors:  Ömer Barış Yücel; Hayri Murat Tunç; Mert Başaran; Necdet Aras
Journal:  Turk J Urol       Date:  2017-04-18

7.  Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months.

Authors:  Christopher Straka; D W Nathan Kim; Robert D Timmerman; Ivan Pedrosa; Corbin Jacobs; James Brugarolas
Journal:  J Clin Oncol       Date:  2013-06-24       Impact factor: 44.544

8.  Accurate three-dimensional virtual reconstruction of surgical field using calibrated trajectories of an image-guided medical robot.

Authors:  Yuanzheng Gong; Danying Hu; Blake Hannaford; Eric J Seibel
Journal:  J Med Imaging (Bellingham)       Date:  2014-12-02

Review 9.  Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.

Authors:  David M Gill; Neeraj Agarwal; Ulka Vaishampayan
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

10.  Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.

Authors:  Marc R Matrana; Tharakeswara Bathala; Matthew T Campbell; Cihan Duran; Aditya Shetty; Purnima Teegavarapu; Sarathi Kalra; Lianchun Xiao; Bradley Atkinson; Paul Corn; Eric Jonasch; Nizar M Tannir
Journal:  BJU Int       Date:  2015-12-13       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.